Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

venetoclax 190Azacitidine 162Cytarabine 127fludarabine 97Cyclophosphamide 75Specimen Handling 68fludarabine phosphate 56Daunorubicin 53Biopsy 49Decitabine 48Whole-Body Irradiation 42Mycophenolic Acid 40Idarubicin 40Busulfan 37Injections 36Tacrolimus 35Granulocyte Colony-Stimulating Factor 35Melphalan 32Stem Cell Transplantation 30gilteritinib 25Filgrastim 25CPX-351 25decitabine and cedazuridine drug combination 23Peripheral Blood Stem Cell Transplantation 22Etoposide 20ivosidenib 19Mitoxantrone 19Cladribine 19Thiotepa 17Sirolimus 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × sodium-iodide symporter × 1 year × Clear all
NCT03017820 2026-05-28

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

Phase 1 Recruiting
99 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡